Scientists Create “Psychedelic Tobacco” Producing Five Compounds at Once
Could one plant really produce multiple psychedelics at the same time?
According to a new study, the answer is yes — at least in the lab.
Researchers have genetically engineered a tobacco plant capable of producing five different psychoactive compounds simultaneously, including those typically found in mushrooms, plants, and even animals. It’s a striking development that shows just how far psychedelic science (and genetic engineering) as come.
But before you imagine a new kind of “super plant” hitting the market, the reality is more nuanced. This breakthrough is less about getting high and more about sustainability, conservation, and future medicine.
One Plant, Five Psychedelics
Portāls study, published in Science Advances, was led by researchers at the Weizmann Institute of Science.
Their goal? To see whether a single plant could be engineered to produce multiple psychedelic indolethylamines: a class of compounds that includes some of the most well-known psychedelics.
The result was a genetically modified tobacco plant that produces:
- Psilocybin and psilocin (no burvju sēnēm)
- Dimethyltryptamine (DMT) (found in ayahuasca plants)
- Bufotenin
- 5-MeO-DMT (associated with the Sonoran Desert toad)
These compounds don’t usually exist together in nature, let alone in a single organism!
“This combination of five psychedelics — I don’t think anyone has ever tried something like it,” said senior author Asaph Aharoni.
How Did They Do It?
To make this happen, the researchers inserted genes responsible for producing these compounds directly into the tobacco plant’s leaves.
These genes come from different organisms across different biological kingdoms:
- Sēnes (like psilocybin mushrooms)
- Plants (like ayahuasca species)
- Animals (like the Sonoran Desert toad)
The result is what some have called “trippy tobacco.” A plant that essentially acts as a biological production platform for multiple psychedelics.
“In one leaf, we get five different psychedelics from three different kingdoms,” Aharoni explained.
Importantly, the modification was limited to the leaves. The plants were designed so these traits are not passed on through seeds, meaning they cannot reproduce this capability naturally.
Fig. 1 (via Science Advances)
Not for Getting High
It might sound like a headline pulled from science fiction, but the intention here isn’t recreational (at least… for now 😉 )
“The goal isn’t to get high,” said co-lead researcher Paula Berman, emphasizing instead the terapeitiskais potenciāls of these compounds.
Substances like psilocybin are already being studied for their ability to treat:
- Depresija
- Trauksme
- PTSD
The challenge is sourcing them.
As interest in psychedelic therapy grows, so does demand. That demand can put pressure on natural ecosystems.
A Sustainability Problem
Many psychedelic compounds come from organisms that are not easy to cultivate at scale.
For example:
- The Sonoran Desert toad is increasingly threatened by habitat loss and overharvesting
- The ayahuasca plant Psychotria viridis is under pressure due to rising tourism and land loss
“The Sonoran Desert toad is increasingly threatened by habitat loss, poaching, and overcollection, raising serious conservation concerns,” the researchers noted.
“Similarly, the slow growing P. viridis faces growing pressure in its native habitats due to land loss and the rising demand for Ayahuasca tourism.”
Producing these compounds in a controlled plant system could offer a cruelty-free and more sustainable alternative.
As the study explains:
“While the concentrations… achieved in this study are lower than those in natural producers, our platform offers a cruelty-free, ecological alternative to harvesting indolethylamines from vulnerable sources.”
Save the Colorado river toad — create psychedelic plants! (via Wikimedia Commons)Why Not Just Synthesize Them?
So, why not simply make these compounds in a lab?
Well, as you probably know, scientists already do. But it’s not always simple.
Chemical synthesis of psychedelics can be:
- Complex
- Expensive
- Time-consuming
Using plants as biological factories could eventually provide a more efficient way to produce these substances at scale.
Still Early Days
We may dream of fields of psychedelic tobacco, however, it’s worth keeping expectations grounded. The plants currently produce very small amounts of these compounds, far less than natural sources.
As bioengineer Andrew Jones (who was not involved in the study) put it:
“That has some cool novelty, but it doesn’t have a lot of practicality.”
He added:
“There are a few psychonauts out there that will get a kick out of it.”
Guilty!
Why Combine Multiple Psychedelics?
Another interesting angle is the combination itself. In nature, these compounds exist separately. But combining them in one organism raises questions about:
- How they interact
- Whether they influence each other’s effects
- What role they play biologically
The researchers are also interested in a bigger mystery: why these compounds exist in nature at all.
Plants, fungi, and animals don’t produce psychedelics for human use. Their ecological purpose is still debated— ranging from defense mechanisms to communication signals. This experiment opens the door to studying these compounds in new ways.
A Glimpse Into the Future of Psychedelics
What this study really represents is a shift in how we think about psychedelics. Rather than relying solely on wild harvesting or complex lab synthesis, scientists are exploring bioengineering as a third path.
One that could:
- Reduce environmental impact
- Protect vulnerable species
- Scale production for medical use
At the same time, it raises important questions about regulation, ethics, and access. Even more so if these technologies become more advanced.
Final Thoughts
A tobacco plant producing five psychedelics might sound like a novelty, but it points to something bigger. We’re entering a phase where psychedelics are no longer just discovered in nature — they’re being reimagined, redesigned, and reproduced through science. (Though research suggest Mother Nature’s offering still comes out on top!)
For now, this “psychedelic tobacco” remains firmly in the lab. The doses are low, the application is experimental, and nobody’s rolling it up. But as research continues, this kind of work could help shape a more sustainable future for psychedelic medicine — one that respects both the compounds and the ecosystems they come from.
